Capricor Therapeutics, Inc. (CAPR)
10.04
+0.03
(+0.30%)
USD |
NASDAQ |
Sep 02, 10:40
Capricor Therapeutics Research and Development Expense (Annual) : 83.50M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 83.50M |
| December 31, 2024 | 49.19M |
| December 31, 2023 | 35.82M |
| December 31, 2022 | 21.82M |
| December 31, 2021 | 13.57M |
| December 31, 2020 | 8.457M |
| December 31, 2019 | 5.142M |
| December 31, 2018 | 12.07M |
| December 31, 2017 | 10.77M |
| December 31, 2016 | 16.04M |
| December 31, 2015 | 13.76M |
| December 31, 2014 | 7.787M |
| December 31, 2013 | 5.197M |
| Date | Value |
|---|---|
| December 31, 2012 | 1.018M |
| December 31, 2011 | 4.129M |
| December 31, 2010 | 4.081M |
| December 31, 2009 | 4.466M |
| December 31, 2008 | 9.478M |
| December 31, 2007 | 5.124M |
| December 31, 2006 | 0.00 |
| December 31, 2005 | 0.00 |
| December 31, 2004 | 0.00 |
| December 31, 2003 | 0.00 |
| December 31, 2002 | 0.00 |
| December 31, 2001 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| REGENXBIO, Inc. | 212.68M |
| Cytokinetics, Inc. | 405.90M |
| Emergent BioSolutions, Inc. | 53.80M |
| Rigel Pharmaceuticals, Inc. | 33.30M |
| United Therapeutics Corp. | 550.00M |